(Adnkronos) - Acquisition strengthens P&F's structural heart portfolio with the addition of the AngelValve™ Augmentation System, a novel transcatheter solution for mitral regurgitation, further expanding the company's portfolio of next-generation transcatheter heart valve therapies and reinforcing its long-term commitment to structural heart innovation.